Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones
  • Policy / Pricing

MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones

Pharmaceutical Technology

Europe contemplates unified drug prices to counter US pressure to spend more.

Read full story

pharminent August 27, 2026 (Last updated: September 1, 2026)

Pharmaceutical Technology

Europe contemplates unified drug prices to counter US pressure to spend more.

Read full story

Post navigation

Previous: FDA Approves Revolution Medicines’ Rasonque, First RAS(ON) Inhibitor for Metastatic Pancreatic Cancer
Next: New data could widen use of AstraZeneca, Amgen immune disease drug

Related Stories

  • Policy / Pricing

MFN affecting Swiss medicines access, says Interpharma

pharminent August 13, 2026
  • Policy / Pricing

Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain

pharminent August 13, 2026
  • Policy / Pricing

Trump signs order that nearly halves childhood immunisation coverage

pharminent August 11, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.